Page 4 - Step Communications News Today : Breaking News, Live Updates & Top Stories | Vimarsana

At this point in the COVID-19 pandemic, with vaccination rates going up and inoculations now available to anyone over fifteen, officials had hoped that case counts would be in serious decline. But no: This week's roundup of data from the Colorado Department of Public Health and Environment shows infections and hospitalizations continuing to rise — and the number of newly identified outbreaks has skyrocketed. The 170 new outbreak sites in the state listed on the CDPHE's just-released April 28 survey represents a 13.166 percent increase in just seven days — and the spike is paced by an exp...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. F-star Granted Composition of Matter Patent for FS118, a Bispecific Antibody Targeting LAG-3 ... F-star Therapeutics, Inc.January 20, 2021 GMT CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Jan. 20, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, today announces the European Patent Office (EPO) has granted a patent with claims protect...

F-star Granted Composition of Matter Patent for FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1 Patent protects Company’s lead clinical asset FS118 throughout Europe CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Jan. 20, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, today announces the European Patent Office (EPO) has granted a patent with claims protecting the composition of matter of F-star’s FS118 molecule th...

(1) Patent protects Company's lead clinical asset FS118 throughout Europe CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Jan. 20, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, today announces the European Patent Office (EPO) has granted a patent with claims protecting the composition of matter of F-star's FS118 molecule throughout Europe. The expiry date of the patent, not including any potential extensions to the standard 2...

*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional bod...